International Journal of Bioorganic Chemistry
Volume 4, Issue 1, June 2019, Pages: 7-13
Received: Feb. 8, 2019;
Accepted: Mar. 11, 2019;
Published: Mar. 28, 2019
Views 207 Downloads 52
Ashwani Kumar Dhingra, Department of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India
Bhawna Chopra, Department of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India
Rameshwar Dass, Department of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India
Prodrugs are the masked forms of active drugs that are designed to be activated once they have been administered into the body by an enzymatic or chemical means. It is a well known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their undesirable pharmacokinetic properties and decrease their toxicity. In most of the cases, prodrugs design involves the introduction of carrier/promoiety by a metabolic liable linkage so that after biotransformation by one or two chemical or enzymatic steps it will lead to the active parent drug. However, some prodrugs lack an obvious promoiety but instead result from a molecular modification of the prodrug itself, which generates a new active compound. This review introduces in depth the rationale behind the use of the promoiety, and also considers the possible problems that can arise from inadequate activation of prodrugs.
Ashwani Kumar Dhingra,
Prodrug Approach: An Alternative to Improve Pharmacokinetic Properties, International Journal of Bioorganic Chemistry.
Vol. 4, No. 1,
2019, pp. 7-13.
B. Malhotra, K. Gandelman, R. Sachse, N. Wood, M. C. Michel, The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine, Curr. Med. Chem. 16 (2009) 4481-4489.
V. J. Stella, W. N. Charman, V. H. Naringrekar, Prodrugs: Do they have advantages in clinical practice? Drugs 29 (1985) 455-473.
K. Huttunen, H. Raunio, J. Rautio, Prodrugs: Design and clinical applications, Pharmacol. Rev. 63 (2011) 750–771.
A. Bertolini, A. Ferreri, S. Guerzoni, R. Tacchi, S. Leone, Paracetamol: New vista of an old drug, CNS Drug Rev. 12 (2006) 250–275.
V. J. Stella, R. T. Burchardt, M. J. Hageman, R. Oliyai, H. Maah, J. W. Tilley, Prodrugs: Challenges and Rewards. Part 1, Springer, New York, 2007.
B. Z. Jolanta, W. Jakub, B. O. Agnieszka, Prodrugs: A challenge for the drug development, Pharmacol. Report 65 (2013) 1–14.
B. Testa, Prodrugs: Bridging pharmacodynamic/pharmacokinetic gaps, Curr. Opin. Chem. Biol. 13 (2009) 338–344.
K. M. Huttunen, H. Raunio, J. Rautio, Prodrugs – from serendipity to rational design, Pharmacol. Rev. 63 (2011) 750-771.
S. Majumdar, K. B. Sloan, Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs, Bioorg. Med. Chem. Lett. 16 (2006) 3590-3594.
S. Peyrottes, D. Egron, I. Lefebvre, G. Gosselin, J. L. Imbach, C. Perigaud, SATE pronucleotide approaches: an overview, Mini Rev. Med. Chem. 4 (2004) 395-408.
J. R. Fozard, BP-294 Ste Civile Bioprojet, Curr. Opin. Investig. Drugs. 1 (2000), 86-89.
A. L. Simplicio, J. M. Clancy, J. F. Gilmer, β-Aminoketones as prodrugs with pH-controlled activation, Int. J. Pharm. 336 (2007) 208-214.
P. Ettmayer, G. L. Amidon, B. Clement, B. Testa, Lessons learned from marketed and investigational prodrugs, J. Med. Chem. 47 (2004) 2393-2404.
K. Beaumont, R. Webster, I. Gardner, K. Dack, Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist, Curr. Drug Metab. 4 (2003) 461-485.
B. M. Liederer, R. T. Borchardt, Enzymes involved in the bioconversion of ester-based prodrugs, J. Pharm. Sci. 95 (2006) 1177-1195.
D. Ecobichon, Relative amounts of hepatic and renal carboxylesterase in mammalian species, Res. Commun. Chem. Pathol. Pharmacol. 3 (1972) 629-636.
T. Heimbach, D. M. Oh, L. Y. Li, N. Rodriguez-Hornedo, G. Garcia, D. Fleisher, Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs, Int. J. Pharm. 261 (2003) 81-92.
R. McComb, G. Bowers, S. Posen, Alkaline Phosphatase, Plenum Press, New York and London, 1979.
P. M. Potter, R. M. Wadkins, Carboxylesterases - detoxifying enzymes and targets for drug therapy, Curr. Med Chem. 13 (2006) 1045-1054.
C. Y. Yang, A. H. Dantzig, C. Pidgeon, Intestinal peptide transport systems and oral drug availability, Pharm. Res. 16 (1999) 1331-1343.
B. Clement, Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines, Drug Metab. Rev. 34 (2002) 565-579.
A. Saqib, C. S. Karigar, M. A. Pasha, M. S. H. Rao, Synthesis, characterization and pharmacological evaluation of palmitic acid derivatives of salicylic acid and anthranilic acid, J. Pharma Res. Opin. 2 (2012) 35-38.
J. M. Shin, G. Sachs, Pharmacology of Proton Pump Inhibitors, Curr. Gastroenterol. Rep. 10 (2008) 528-534.
H. Yano, F. Hirayama, H. Arima, K. Uekama, Hydrolysis behavior of prednisolone 21-hemisuccinate/beta-cyclodextrin amide conjugate: involvement of intramolecular catalysis of amide group in drug release, Chem. Pharm. Bull. (Tokyo), 48 (2000) 1125-1128.
I. S. Krylov, B. A. Kashemirov, J. M. Hilfinger, C. E. McKenna, Evolution of an Amino Acid-based Prodrug Approach: Stay Tuned, Mol. Pharm. 10 (2013) 445-458.
V. Jon, U. N. Carsten, I. Truls, L. Tore, S. Bente, L. Kristina, Dipeptidomimetic Ketomethylene Isosteres as Pro-moieties for Drug Transport via the Human Intestinal Di-/Tripeptide Transporter hPEPT1: Design, Synthesis, Stability, and Biological Investigations, J. Med. Chem. 47 (2004) 4755-4765.
J. P. Michael, K. F. D. Amy, A. M. Nicholas, A. S. Carol, T. R. Ronald, Ribonucleoside 3′-Phosphates as Pro-Moieties for an Orally Administered Drug, Chem. Med. Chem. 7 (2012) 1361-1364.